Seeking Alpha

Illumina: An Excellent Profit Margin And The Sequencing Genome Market Will Unlock Value

Illumina exhibits better profitability ratios than many of its peers, which indicates that the company could continue to invest in its operations. In Q3 2025, ILMN raised its EPS to $4.65-$4.75, ...

Illumina advances preventive genomics through strategic consortium with Veritas Genetics

Illumina, Inc. (NASDAQ: ILMN) today announced a strategic collaboration with Veritas Genetics Powered By Fuze Health to form a consortium that aims to bring preventive genomics into everyday ...
EurekAlert!

Illumina and the San Diego Zoo Wildlife Alliance partner to sequence the Frozen Zoo®, supporting critical conservation genetics efforts globally

SAN DIEGO, Feb. 3, 2026 — Illumina (NASDAQ: ILMN) today announced a sequencing agreement with the San Diego Zoo Wildlife Alliance (SDZWA)’s Frozen Zoo®. The 50-year-old biobank is the world’s most ...

Illumina and Labcorp expand collaboration to broaden access to precision oncology testing

Illumina, Inc. (NASDAQ: ILMN) and Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration to advance precision oncology ...
Pharmabiz

Illumina and Labcorp expand collaboration to advance precision oncology through innovative applications of NGS solutions

Illumina and Labcorp expand collaboration to advance precision oncology through innovative applications of NGS solutions: San Diego Friday, March 20, 2026, 15:00 Hrs [IST] Illumin ...
StockStory.org on MSN

Life sciences tools & services stocks Q4 earnings: Illumina (NASDAQ:ILMN) firing on all cylinders

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look ...
GEN

At ASHG, Illumina to Share Updates to Sequencing, Proteomics, and Single-Cell Technologies

During the meeting, Steve Barnard, PhD, Illumina’s CTO will provide new details about the company’s constellation mapped read technology. He will be joined by Niall Lennon, PhD, chair and CSO of Broad ...

Illumina Stock Climbs 44.8% in a Year: What's Driving the Rally?

Shares of IlluminaILMN have risen 44.8% over the past year, reflecting strong momentum. The stock has outpaced the industry’s ...
Morningstar

Illumina's Moat in Sequencing Remains Narrow

Illumina continues to focus on transforming human health practices through its leadership of genomic sequencing and related applications. The firm provides a broad range of instruments and related ...
The New York Times

Gene-Sequencing Company Illumina to Sell Cancer Test Developer

The move came two days after a court upheld the Federal Trade Commission’s challenge to the deal on antitrust grounds. By Nicole Sperling Illumina, the leading producer of gene-sequencing machines, ...
San Diego Union-Tribune

San Diego has a new CEO in town. Here’s what financial analysts are saying about Illumina’s next leader

Illumina, San Diego’s DNA-sequencing giant, has a new boss. Illumina’s board tapped Jacob Thaysen, a seasoned life science executive, to lead the $25 billion biotechnology company starting on Sept. 25 ...